HealthLinx' OvPlex shows 93% diagnostic efficacy
Australian diagnostics company HealthLinx says that it has received independent verification of the accuracy of its early-stage ovarian cancer assay, OvPlex. The finding is based on a review of data from a Phase II biomarker trial conducted late last year.
In the study, which was reviewed by independent statistics and bioinformatics firm Emphron Informatics, OvPlex demonstrated a diagnostic efficacy of 92.8%, sensitivity of 89.2% and specificity of 93.9%.
HealthLinx' managing director, Nick Gatsios, said: "93.9% specificity for early-stage ovarian cancer diagnosis is a breakthrough," adding that "our test identified four patients that were missed by CA125 [the current gold standard blood test] and eliminated 11 patients miss-classified by CA125."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze